---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025270"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2026-05-26T21:08:04+00:00"
generated_at: "2026-05-26T21:17:07.073628+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.75
confidence: "low"
source: SEC EDGAR
---

# Lipocine Presents Phase 3 Data for LPCN 1154 (Oral Brexanolone) for Postpartum Depression at ASCP

## Summary
- May 26, 2026: Company highlighted results from placebo-controlled Phase 3 trial of LPCN 1154 for PPD at ASCP Annual Meeting.
- The presentation and poster are furnished as exhibits but not included in the 8-K text; specific efficacy and safety endpoints are unconfirmed.
- LPCN 1154 is an oral rapid-acting neuroactive steroid (brexanolone); this readout supports potential label expansion.
- Stock impact uncertain without actual data; materiality depends on trial outcomes not disclosed in this filing.

## SEC filing metadata
- accession: 0001493152-26-025270
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2026-05-26T21:08:04+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.75
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/0001493152-26-025270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025270
- JSON: https://secwatch.observer/filing/0001493152-26-025270.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.